

RECEIVED  
CENTRAL FAX CENTER  
AUG 01 2007

**J.C. PATENTS**  
4 VENTURE, SUITE 250  
IRVINE, CALIFORNIA 92618  
TEL.: (949) 660-0761  
FAX: (949) 660-0809  
E-MAIL: [jcpi@email.msn.com](mailto:jcpi@email.msn.com)

**CERTIFICATE OF TRANSMISSION****August 1, 2007**

Atty Docket No. :	JCLA21671
Appl. No. :	10/599,050
Filing Date :	September, 18, 2006
Pages :	Cover + 14

**BY FACSIMILE ONLY**

Fax No. :	571-273-8300
Attention :	EXAMINER :
Group Unit :	
From :	Jiawei Huang, Reg. No. 43,330
MESSAGE :	Enclosed herewith is an Information Disclosure Statement with 4 references in 14 pages.

Sir:

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office on **August 1, 2007** at the above indicated fax number.

Sign by:                     

Michelle Chang

**Note:** This facsimile transmission is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this transmission in error, please kindly notify us immediately, and return the original message to us at the above address. We greatly appreciate your cooperation.

RECEIVED  
CENTRAL FAX CENTER  
AUG 01 2007

002/015

PATENT

Docket No.: JCLA21671

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : KAZUYA HOSOKAWA et al.  
Application No. : 10/599,050  
Filed : September 18, 2006  
For : THROMBIN DERIVATIVES AND MEDICINAL COMPOSITION  
: CONTAINING THE SAME

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Enclosed is a PTO Form 1449 listing ( 4 ) references that are also attached. Applicants submit the reference(s) in compliance with their duty of disclosure pursuant to 37 CFR §1.56 and 1.97. The Examiner is requested to make the citation(s) of official record.

This IDS is being submitted before first Office Action. Thus, no fee is due. However, if a first Office Action has been sent, the Commissioner is authorized to charge any necessary fee in connection with the submission of the IDS to Account No. 50-0710 (Order No. JCLA21671).

The submission of the references should not be interpreted as admitting them as prior art.

Respectfully submitted,  
J.C. Patents

Dated: 8-1-2007

By:   
Jiawei Huang  
Registration No. 43,330

Correspondence Address:  
4 Venture, Suite 250  
Irvine, CA 92618  
Tel: (949) 660-0761

RECEIVED  
CENTRAL FAX CENTER  
AUG 01 2007

003/015

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO.: JCLA21671	APPLICATION No.: 10/599,050
	APPLICANT: KAZUYA HOSOKAWA et al.	
	FILING DATE: September 18, 2006	GROUP:

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	6,946,279	09/20/05	Kazuya Hosokawa	435	214	
	6,086,871	07/11/00	Bernhard Fischer et al.	424	94.64	
	5,256,766	10/26/93	Shaun R. Coughlin	530	327	

## NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.	T
		ZHONG-RU GAN et al., "Importance of the Arg-Gly-Asp Triplet in Human Thrombin for Maintenance of Structure and Function" 1993 by Academic Press, Inc., ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, Vol. 301, No. 2, March, 1993, pp. 228-236	✓

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.